Matthew K. Fust - 14 Sep 2023 Form 3 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust
Issuer symbol
NMRA
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
3
Filing time
14 Sep 2023, 18:57:13 UTC
Previous filing
21 Jun 2023
Next filing
11 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 3,783 $8.32 Direct F1, F2
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 8,005 $8.79 Direct F1, F2
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 95,586 $2.52 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option are fully vested and exercisable.
F2 Reflects a 1-for-7.8463 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on September 8, 2023.
F3 1/36th of the shares subject to the option vest on each monthly anniversary measured from December 23, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

Remarks:

Exhibit 24 - Power of Attorney